RecruitingPhase 1NCT06180174

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Phase I Clinical Study of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) Formulation for the Treatment of Relapsed/Refractory CD19-positive B-cell Non-Hodgkin Lymphoma (B-NHL)

Sponsor

Chongqing Precision Biotech Co., Ltd

Enrollment

24 participants

Start Date

Dec 31, 2023

Study Type

INTERVENTIONAL

Conditions

Non-Hodgkin Lymphoma B-cell Lymphoma

Summary

This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing CAR-T cell therapy — a treatment where your own immune cells are reprogrammed to fight cancer — for adults with B-cell lymphoma that has come back or stopped responding to previous treatments. The CAR-T cells in this trial are designed to attack a protein called CD19 that is found on the surface of these cancer cells. **You may be eligible if...** - You are 18 or older with confirmed B-cell lymphoma - Your lymphoma has relapsed (come back) or is refractory (not responding to treatment) - You have received at least two prior lines of treatment - Your cancer tests positive for the CD19 protein **You may NOT be eligible if...** - Your lymphoma does not express the CD19 marker - You have active, uncontrolled infections - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.